Compare BHC & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BHC | MESO |
|---|---|---|
| Founded | N/A | 2004 |
| Country | Canada | Australia |
| Employees | N/A | 81 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1996 | N/A |
| Metric | BHC | MESO |
|---|---|---|
| Price | $4.78 | $15.45 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 2.1M | 137.6K |
| Earning Date | 04-29-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 423.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,724,000,000.00 | N/A |
| Revenue This Year | $4.61 | $629.74 |
| Revenue Next Year | N/A | $30.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.57 | $10.32 |
| 52 Week High | $8.69 | $21.50 |
| Indicator | BHC | MESO |
|---|---|---|
| Relative Strength Index (RSI) | 36.06 | 59.54 |
| Support Level | N/A | $13.71 |
| Resistance Level | $6.31 | $16.11 |
| Average True Range (ATR) | 0.19 | 0.49 |
| MACD | -0.04 | 0.16 |
| Stochastic Oscillator | 26.06 | 88.92 |
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.